^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SRF617

    i
    Other names: SRF617
    Associations

    News

    Trials
    Company:
    Coherus Biosci
    Drug class:
    CD39 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    KEYNOTE-A62: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=85, Completed, Surface Oncology | Active, not recruiting --> Completed | N=177 --> 85
    Trial completion • Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • gemcitabine • albumin-bound paclitaxel • SRF617
    over1year
    Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Surface Oncology | Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> Jul 2023 | Trial primary completion date: Nov 2023 --> May 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CAST (Calpastatin)
    |
    Yutuo (zimberelimab) • etrumadenant (AB928) • SRF617
    over1year
    KEYNOTE-A62: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=177, Active, not recruiting, Surface Oncology | Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Aug 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • gemcitabine • albumin-bound paclitaxel • SRF617
    2years
    SRF617-101: Study of SRF617 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=177, Recruiting, Surface Oncology | N=100 --> 177
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • gemcitabine • albumin-bound paclitaxel • SRF617
    over2years
    First-in-human phase 1 trial of SRF617, a potent inhibitor of CD39 activity, as monotherapy or in combination, in patients (pts) with advanced solid tumors. (ESMO-IO 2021)
    Methods Pts with advanced solid tumors were enrolled in a phase 1 dose-escalation study of SRF617 (NCT04336098) to establish preliminary safety as monotherapy as well as in combination with gemcitabine + nab-paclitaxel (GA) or pembrolizumab (P) and to identify doses suitable for monotherapy and combination expansion cohorts...Legal entity responsible for the study Surface Oncology, Cambridge, MA, USA. Funding Surface Oncology, Cambridge, MA, USA.
    Clinical • P1 data
    |
    ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • leucovorin calcium • SRF617
    over2years
    The fully human antibody SRF617 is a potent inhibitor of ecto-enzyme CD39 in vivo (SITC 2021)
    Wild-type mice bearing subcutaneous (s.c.) KPC1245 tumors were treated with anti-murine CD39 antibody, alone or in combination with gemcitabine. These studies demonstrate the therapeutic potential of targeting CD39 for the treatment of cancer. SRF617 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors (NCT04336098) and in combination with chemotherapy in patients with pancreatic cancer.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    gemcitabine • SRF617
    4years
    [VIRTUAL] SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies (AACR-II 2020)
    Inhibition of CD39 potentiates the activity of chemotherapy and immunotherapy agents to improve tumor growth inhibition and survival in mice. These findings support future clinical studies of SRF617 as monotherapy and in combination with other therapeutic agents in treating patients with cancer.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD73 (5'-Nucleotidase Ecto)
    |
    SRF617